Richard Rifkind

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Chemicals & Drugs

Physiology

Living Beings

Mice

Anatomy

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Marrocco Deborah L; Tilley Wayne D; Bianco-Miotto Tina; Evdokiou Andreas; Scher Howard I; Rifkind Richard A; Marks Paul A; Richon Victoria M; Butler Lisa M
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Kutko Martha C; Glick Richard D; Butler Lisa M; Coffey Dennis C; Rifkind Richard A; Marks Paul A; Richon Victoria M; LaQuaglia Michael P
Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro.
Kelly Wm Kevin; Richon Victoria M; O'Connor Owen; Curley Tracy; MacGregor-Curtelli Barbara; Tong William; Klang Mark; Schwartz Lawrence; Richardson Stacie; Rosa Eddie; Drobnjak Marija; Cordon-Cordo Carlos; Chiao Judy H; Rifkind Richard; Marks Paul A; Scher Howard
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Richard Rifkind (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2007: Marrocco Deborah L; Tilley Wayne D; Bianco-Miotto Tina; Evdokiou Andreas; Scher Howard I; Rifkind Richard A; Marks Paul A; Richon Victoria M; Butler Lisa M
Suberoylanilide hydroxamic acid (vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation.
Molecular cancer therapeutics 2007;6(1):51-60.
2003: Kutko Martha C; Glick Richard D; Butler Lisa M; Coffey Dennis C; Rifkind Richard A; Marks Paul A; Richon Victoria M; LaQuaglia Michael P
Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(15):5749-55.
2003: Kelly Wm Kevin; Richon Victoria M; O'Connor Owen; Curley Tracy; MacGregor-Curtelli Barbara; Tong William; Klang Mark; Schwartz Lawrence; Richardson Stacie; Rosa Eddie; Drobnjak Marija; Cordon-Cordo Carlos; Chiao Judy H; Rifkind Richard; Marks Paul A; Scher Howard
Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3578-88.
2002: Butler Lisa M; Zhou Xianbo; Xu Wei-Sheng; Scher Howard I; Rifkind Richard A; Marks Paul A; Richon Victoria M
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(18):11700-5.
2002: Cohen Leonard A; Marks Paul A; Rifkind Richard A; Amin Shantu; Desai Dhimant; Pittman Brian; Richon Victoria M
Suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, suppresses the growth of carcinogen-induced mammary tumors.
Anticancer research 2002;22(3):1497-504.
2001: Marks P; Rifkind R A; Richon V M; Breslow R; Miller T; Kelly W K
Histone deacetylases and cancer: causes and therapies.
Nature reviews. Cancer 2001;1(3):194-202.
2001: Munster P N; Troso-Sandoval T; Rosen N; Rifkind R; Marks P A; Richon V M
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells.
Cancer research 2001;61(23):8492-7.
2001: He L Z; Tolentino T; Grayson P; Zhong S; Warrell R P; Rifkind R A; Marks P A; Richon V M; Pandolfi P P
Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia.
The Journal of clinical investigation 2001;108(9):1321-30.
2001: Marks P A; Richon V M; Breslow R; Rifkind R A
Histone deacetylase inhibitors as new cancer drugs.
Current opinion in oncology 2001;13(6):477-83.
2001: Zhou X; Marks P A; Rifkind R A; Richon V M
Cloning and characterization of a histone deacetylase, HDAC9.
Proceedings of the National Academy of Sciences of the United States of America 2001;98(19):10572-7.
2001: Coffey D C; Kutko M C; Glick R D; Butler L M; Heller G; Rifkind R A; Marks P A; Richon V M; La Quaglia M P
The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid.
Cancer research 2001;61(9):3591-4.
2001: Butler L M; Webb Y; Agus D B; Higgins B; Tolentino T R; Kutko M C; LaQuaglia M P; Drobnjak M; Cordon-Cardo C; Scher H I; Breslow R; Richon V M; Rifkind R A; Marks P A
Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(4):962-70.
2001: Marks P A; Rifkind R A; Richon V M; Breslow R
Inhibitors of histone deacetylase are potentially effective anticancer agents.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(4):759-60.
2001: Richon V M; Zhou X; Rifkind R A; Marks P A
Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers.
Blood cells, molecules & diseases 2001;27(1):260-4.
2000: Zhou X; Richon V M; Wang A H; Yang X J; Rifkind R A; Marks P A
Histone deacetylase 4 associates with extracellular signal-regulated kinases 1 and 2, and its cellular localization is regulated by oncogenic Ras.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(26):14329-33.
2000: Coffey D C; Kutko M C; Glick R D; Swendeman S L; Butler L; Rifkind R; Marks P A; Richon V M; LaQuaglia M P
Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro.
Medical and pediatric oncology 2000;35(6):577-81.
2000: Butler L M; Agus D B; Scher H I; Higgins B; Rose A; Cordon-Cardo C; Thaler H T; Rifkind R A; Marks P A; Richon V M
Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
Cancer research 2000;60(18):5165-70.
2000: Richon V M; Sandhoff T W; Rifkind R A; Marks P A
Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(18):10014-9.
2000: Marks P A; Richon V M; Rifkind R A
Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells.
Journal of the National Cancer Institute 2000;92(15):1210-6.
2000: Zhou X; Richon V M; Rifkind R A; Marks P A
Identification of a transcriptional repressor related to the noncatalytic domain of histone deacetylases 4 and 5.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(3):1056-61.
1999: Cohen L A; Amin S; Marks P A; Rifkind R A; Desai D; Richon V M
Chemoprevention of carcinogen-induced mammary tumorigenesis by the hybrid polar cytodifferentiation agent, suberanilohydroxamic acid (SAHA).
Anticancer research 1999;19(6B):4999-5005.
1999: Finnin M S; Donigian J R; Cohen A; Richon V M; Rifkind R A; Marks P A; Breslow R; Pavletich N P
Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors.
Nature 1999;401(6749):188-93.
1999: Glick R D; Swendeman S L; Coffey D C; Rifkind R A; Marks P A; Richon V M; La Quaglia M P
Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma.
Cancer research 1999;59(17):4392-9.
1999: Zhou X; Richon V M; Ngo L; Rifkind R A; Marks P A
Cloning of the cDNA encoding phenylalanyl tRNA synthetase regulatory alpha-subunit-like protein whose expression is down-regulated during differentiation.
Gene 1999;233(1-2):13-9.
1999: Webb Y; Zhou X; Ngo L; Cornish V; Stahl J; Erdjument-Bromage H; Tempst P; Rifkind R A; Marks P A; Breslow R; Richon V M
Photoaffinity labeling and mass spectrometry identify ribosomal protein S3 as a potential target for hybrid polar cytodifferentiation agents.
The Journal of biological chemistry 1999;274(20):14280-7.
1999: Marks P A; Richon V M; Breslow R; Rifkind R A
Hybrid polar inducers of transformed cell differentiation/apoptosis. From the cell to the clinic.
Comptes rendus de l'Académie des sciences. Série III, Sciences de la vie 1999;322(2-3):161-5.
1998: Richon V M; Emiliani S; Verdin E; Webb Y; Breslow R; Rifkind R A; Marks P A
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(6):3003-7.
1998: Siegel D S; Zhang X; Feinman R; Teitz T; Zelenetz A; Richon V M; Rifkind R A; Marks P A; Michaeli J
Hexamethylene bisacetamide induces programmed cell death (apoptosis) and down-regulates BCL-2 expression in human myeloma cells.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(1):162-6.
1997: Richon V M; Russo P; Venta-Perez G; Cordon-Cardo C; Rifkind R A; Marks P A
Two cytodifferentiation agent-induced pathways, differentiation and apoptosis, are distinguished by the expression of human papillomavirus 16 E7 in human bladder carcinoma cells.
Cancer research 1997;57(13):2789-98.
1996: Marks P A; Richon V M; Rifkind R A
Induced differentiation of cancer cells: second generation potent hybrid polar compounds target cell cycle regulators.
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 1996;5 Suppl 2():75-7.
1996: Richon V M; Webb Y; Merger R; Sheppard T; Jursic B; Ngo L; Civoli F; Breslow R; Rifkind R A; Marks P A
Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(12):5705-8.
1996: Marks P A; Richon V M; Rifkind R A
Cell cycle regulatory proteins are targets for induced differentiation of transformed cells: Molecular and clinical studies employing hybrid polar compounds.
International journal of hematology 1996;63(1):1-17.
1996: Rifkind R A; Richon V M; Marks P A
Induced differentiation, the cell cycle, and the treatment of cancer.
Pharmacology & therapeutics 1996;69(2):97-102.
1994: Rifkind R A
Clinical excellence and research: one and indivisible.
Annals of the New York Academy of Sciences 1994;729():162-3; discussion 170-4.
1994: Kiyokawa H; Richon V M; Rifkind R A; Marks P A
Suppression of cyclin-dependent kinase 4 during induced differentiation of erythroleukemia cells.
Molecular and cellular biology 1994;14(11):7195-203.
1994: Marks P A; Richon V M; Kiyokawa H; Rifkind R A
Inducing differentiation of transformed cells with hybrid polar compounds: a cell cycle-dependent process.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(22):10251-4.
1993: Leng L; Yu F; Dong L; Busquets X; Osada S; Richon V M; Marks P A; Rifkind R A
Differential modulation of protein kinase C isoforms in erythroleukemia during induced differentiation.
Cancer research 1993;53(22):5554-8.
1993: Kiyokawa H; Richon V M; Venta-Perez G; Rifkind R A; Marks P A
Hexamethylenebisacetamide-induced erythroleukemia cell differentiation involves modulation of events required for cell cycle progression through G1.
Proceedings of the National Academy of Sciences of the United States of America 1993;90(14):6746-50.
1992: Michaeli J; Busquets X; Orlow I; Younes A; Colomer D; Marks P A; Rifkind R A; Kolesnick R N
A rise and fall in 1,2-diacylglycerol content signal hexamethylene bisacetamide-induced erythropoiesis.
The Journal of biological chemistry 1992;267(33):23463-6.
1992: Andreeff M; Stone R; Michaeli J; Young C W; Tong W P; Sogoloff H; Ervin T; Kufe D; Rifkind R A; Marks P A
Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogenous leukemia: a phase II clinical trial with a differentiation-inducing agent.
Blood 1992;80(10):2604-9.
1992: Richon V M; Rifkind R A; Marks P A
Expression and phosphorylation of the retinoblastoma protein during induced differentiation of murine erythroleukemia cells.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1992;3(7):413-20.
1992: Kiyokawa H; Ngo L; Kurosaki T; Rifkind R A; Marks P A
Changes in p34cdc2 kinase activity and cyclin A during induced differentiation of murine erythroleukemia cells.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1992;3(6):377-83.
1992: Kiyokawa H; Busquets X; Powell C T; Ngo L; Rifkind R A; Marks P A
Cloning of a D-type cyclin from murine erythroleukemia cells.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(6):2444-7.
1992: Powell C T; Leng L; Dong L; Kiyokawa H; Busquets X; O'Driscoll K; Marks P A; Rifkind R A
Protein kinase C isozymes epsilon and alpha in murine erythroleukemia cells.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(1):147-51.
1991: Breslow R; Jursic B; Yan Z F; Friedman E; Leng L; Ngo L; Rifkind R A; Marks P A
Potent cytodifferentiating agents related to hexamethylenebisacetamide.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(13):5542-6.
1991: Richon V M; Weich N; Leng L; Kiyokawa H; Ngo L; Rifkind R A; Marks P A
Characteristics of erythroleukemia cells selected for vincristine resistance that have accelerated inducer-mediated differentiation.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(5):1666-70.
1990: Weich N; Marks P A; Rifkind R A
Relationship between globin mRNA accumulation and commitment to terminal cell differentiation in inducer sensitive and resistant erythroleukemia variants.
Blood 1990;76(2):302-6.
1990: Michaeli J; Lebedev Y B; Richon V M; Chen Z X; Marks P A; Rifkind R A
Conversion of differentiation inducer resistance to differentiation inducer sensitivity in erythroleukemia cells.
Molecular and cellular biology 1990;10(7):3535-40.
1990: Melloni E; Pontremoli S; Sparatore B; Patrone M; Grossi F; Marks P A; Rifkind R A
Introduction of the beta isozyme of protein kinase C accelerates induced differentiation of murine erythroleukemia cells.
Proceedings of the National Academy of Sciences of the United States of America 1990;87(12):4417-20.
1990: Marks P A; Rifkind R A
Approaches to more effective induction of cytodifferentiation of transformed cells and potential for cancer treatment.
[Rinsho ketsueki] The Japanese journal of clinical hematology 1990;31(4):401-8.
1990: Marks P A; Rifkind R A
Role of differentiation induction in tumor suppression.
Immunology series 1990;51():201-16.
1989: Melloni E; Pontremoli S; Viotti P L; Patrone M; Marks P A; Rifkind R A
Differential expression of protein kinase C isozymes and erythroleukemia cell differentiation.
The Journal of biological chemistry 1989;264(31):18414-8.
1989: Marks P A; Breslow R; Rifkind R A; Ngo L; Singh R
Polar/apolar chemical inducers of differentiation of transformed cells: strategies to improve therapeutic potential.
Proceedings of the National Academy of Sciences of the United States of America 1989;86(16):6358-62.
1989: Marks P A; Rifkind R A
Induced differentiation of erythroleukemia cells by hexamethylene bisacetamide: a model for cytodifferentiation of transformed cells.
Environmental health perspectives 1989;80():181-8.
1989: Richon V M; Ramsay R G; Rifkind R A; Marks P A
Modulation of the c-myb, c-myc and p53 mRNA and protein levels during induced murine erythroleukemia cell differentiation.
Oncogene 1989;4(2):165-73.
1989: Marks P A; Michaeli J; Jackson J; Richon V M; Rifkind R A
Induced differentiation of murine erythroleukemia cells (MELC) by polar compounds: marked increased sensitivity of vincristine resistant MELC.
Progress in clinical and biological research 1989;316B():171-81.
1988: Young C W; Fanucchi M P; Declan Walsh T; Baltzer L; Yaldaei S; Stevens Y W; Gordon C; Tong W; Rifkind R A; Marks P A
Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight-day intervals.
Cancer research 1988;48(24 Pt 1):7304-9.
1988: Marks P A; Rifkind R A
Hexamethylene bisacetamide-induced differentiation of transformed cells: molecular and cellular effects and therapeutic application.
International journal of cell cloning 1988;6(4):230-40.
1988: Melloni E; Pontremoli S; Damiani G; Viotti P; Weich N; Rifkind R A; Marks P A
Vincristine-resistant erythroleukemia cell line has marked increased sensitivity to hexamethylenebisacetamide-induced differentiation.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(11):3835-9.
1988: Weich N; Marks P A; Rifkind R A
Regulation of murine alpha-, beta major-, and beta minor-globin gene expression.
Biochemical and biophysical research communications 1988;150(1):204-11.
1987: Marks P A; Sheffery M; Rifkind R A
Induction of transformed cells to terminal differentiation and the modulation of gene expression.
Cancer research 1987;47(3):659-66.
1987: Marks P A; Ramsay R; Sheffery M; Rifkind R A
Changes in gene expression during hexamethylene bisacetamide induced erythroleukemia differentiation.
Progress in clinical and biological research 1987;251():253-68.
1987: Marks P A; Sheffery M; Ramsay R; Ikeda K; Rifkind R A
Induction of transformed cells to terminal differentiation.
Annals of the New York Academy of Sciences 1987;511():246-55.
1987: Rifkind R A; Sheffery M; Marks P A
Induced erythroleukemia differentiation: cellular and molecular aspects.
Blood cells 1987;13(1-2):277-84.
1986: Ramsay R G; Ikeda K; Rifkind R A; Marks P A
Changes in gene expression associated with induced differentiation of erythroleukemia: protooncogenes, globin genes, and cell division.
Proceedings of the National Academy of Sciences of the United States of America 1986;83(18):6849-53.
1985: Kaneda T; Murate T; Sheffery M; Brown K; Rifkind R A; Marks P A
Gene expression during terminal differentiation: dexamethasone suppression of inducer-mediated alpha 1- and beta maj-globin gene expression.
Proceedings of the National Academy of Sciences of the United States of America 1985;82(15):5020-4.
1985: Marks P A; Sheffery M; Rifkind R A
Modulation of gene expression during terminal cell differentiation.
Progress in clinical and biological research 1985;191():185-203.
1984: Salditt-Georgieff M; Sheffery M; Krauter K; Darnell J E; Rifkind R; Marks P A
Induced transcription of the mouse beta-globin transcription unit in erythroleukemia cells. Time-course of induction and of changes in chromatin structure.
Journal of molecular biology 1984;172(4):437-50.
1984: Sheffery M; Marks P A; Rifkind R A
Gene expression in murine erythroleukemia cells. Transcriptional control and chromatin structure of the alpha 1-globin gene.
Journal of molecular biology 1984;172(4):417-36.
1984: Rifkind R A; Sheffery M; Marks P A
Induced differentiation of murine erythroleukemia cells: cellular and molecular mechanisms.
Advances in cancer research 1984;42():149-66.
1983: Sheffery M; Rifkind R A; Marks P A
Hexamethylenebisacetamide-resistant murine erythroleukemia cells have altered patterns of inducer-mediated chromatin changes.
Proceedings of the National Academy of Sciences of the United States of America 1983;80(11):3349-53.
1983: Profous-Juchelka H R; Reuben R C; Marks P A; Rifkind R A
Transcriptional and post-transcriptional regulation of globin gene accumulation in murine erythroleukemia cells.
Molecular and cellular biology 1983;3(2):229-32.
1983: Rifkind R A; Sheffery M; Profous-Juchelka H R; Reuben R C; Marks P A
Regulation of globin gene expression during induced erythroid cell differentiation.
Progress in clinical and biological research 1983;134():183-92.
1983: Rifkind R A; Sheffery M; Profous-Juchelka H R; Reuben R C; Marks P A
Induction of globin gene expression during erythroid cell differentiation.
Annals of the New York Academy of Sciences 1983;411():141-9.
1982: Sheffery M; Rifkind R A; Marks P A
Murine erythroleukemia cell differentiation: DNase I hypersensitivity and DNA methylation near the globin genes.
Proceedings of the National Academy of Sciences of the United States of America 1982;79(4):1180-4.
1981: Giri J G; Reuben R C; Rifkind R A; Marks P A
DNA polymerase activities during induced differentiation in murine erythroleukemia cells.
Experimental cell research 1981;132(1):137-46.
1980: Reuben R C; Rifkind R A; Marks P A
Chemically induced murine erythroleukemic differentiation.
Biochimica et biophysica acta 1980;605(3):325-46.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Richard Rifkind

Research Profile (preview)

Disorders

Chemicals & Drugs

Physiology

Living Beings

Anatomy

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Richard Rifkind (preview)

All Publications